WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

TD Cowen initiated coverage of Upstream Bio (UPB) with a Buy rating. The firm says the company’s verekitug is a “differentiated fast follower” with greater potency and extended dosing ...

Early preclinical and clinical data for verekitug indicate a potential for even greater efficacy than Tezspire. Upstream Bio ...

Nov. 07, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders ...

Upstream Bio’s (NASDAQ:UPB – Get Free Report) quiet period is set to end on Wednesday, November 20th. Upstream Bio had issued 15,000,000 shares in its initial public offering on October 11th.